FBIO

Fortress Biotech Inc

1.84

Nov 05 • 3:59 PM ET -0.13 (-6.60%)

1.90

Aftermarket • 7:07 PM ET +0.06 (3.26%)

Healthcare Biotechnology USA Micro NASD

Peers: VRCA PTHS SLGL ARQT ROIV HRTX BFRI EOLS ETON AYTU

| Held by: VTI VXF IWC BSVO AVSC

Scroll to Statements

Index	-
Market Cap	61.36M
Enterprise Value	-39.95M
Income	103.37M
Sales	68.47M
Book/sh	4.93
Cash/sh	5.89
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	78
IPO	Nov 17, 2011

P/E	0.69
Forward P/E	-
PEG	-
P/S	0.90
P/B	0.37
P/C	0.31
P/FCF	0.51
EV/EBITDA	-
EV/Sales	-0.58
Quick Ratio	3.83
Current Ratio	3.96
Debt/Eq	0.32
LT Debt/Eq	0.28
Option/Short	Yes / Yes

EPS (ttm)	2.66
EPS next Y	-1.00
EPS next Q	-0.27
EPS this Y	3742.86%
EPS next Y	-139.22%
EPS next 5Y	-
EPS past 3/5Y	83.35% 62.98%
Sales past 3/5Y	-5.83% 6.77%
EPS Y/Y TTM	401.39%
Sales Y/Y TTM	15.46%
EPS Q/Q	-117.40%
Sales Q/Q	14.04%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	60.00% 2.28%

Insider Own	30.90%
Insider Trans	0.00%
Inst Own	23.84%
Inst Trans	2.93%
ROA	46.92%
ROE	107.48%
ROIC	53.19%
Gross Margin	58.88%
Oper. Margin	-42.86%
Profit Margin	150.97%
SMA20	-5.41%
SMA50	-17.58%
SMA200	-33.23%
Trades

Shs Outstand	33.31M
Shs Float	23.04M
Short Float	19.63%
Short Ratio	12.79
Short Interest	4.52M
52W High	4.53 -59.38%
52W Low	1.83 0.55%
Volatility	6.51% 4.66%
ATR (14)	0.10
RSI (14)	35.34
Beta	1.26
Rel Volume	0.87
Avg Volume	353.66K
Volume	307,440

Perf Week	-8.00%
Perf Month	-9.80%
Perf Quarter	-31.09%
Perf Half Y	-23.33%
Perf YTD	-49.73%
Perf Year	-25.81%
Perf 3Y	-17.86%
Perf 5Y	-96.58%
Perf 10Y	-93.99%
Recom	1.00
Target Price	5.00
Prev Close	1.97
Price	1.84
Change %	-6.60%

Consensus

Strong Buy

Avg. Price Target

$5.00

Implied Upside

+171.7%

Analysts8incl. previous ratings

Rating Distribution8 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 15, 2024	Resumed	RROTH MKM	Buy	$10	+443.5%
Aug 04, 2022	Initiated	LLadenburg Thalmann	Buy	$6	+226.1%
Oct 02, 2020	Initiated	TThe Benchmark Company	Buy	$9	+389.1%
Dec 18, 2019	Initiated	BB. Riley FBR	Buy	$9	+389.1%
Feb 28, 2018	Initiated	BB. Riley FBR, Inc.	Buy	$10	+443.5%
Jul 11, 2017	Initiated	RRodman & Renshaw	Buy	$11	+497.8%
Mar 22, 2017	Initiated	JJMP Securities	Mkt Outperform
Oct 03, 2016	Initiated	RROTH Capital	Buy	$9	+389.1%

Nov-05-26 08:30AM	Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 (GlobeNewswire) -6.60%
Sep-08-26 04:05PM	Journey Medical Corporation to Participate in September 2026 Investor Conferences (GlobeNewswire)
08:00AM	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-13-26 05:05PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press) +8.36%
04:05PM	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Loading…
Aug-12-26 04:01PM	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.36%
Aug-05-26 08:30AM	Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire)
Jul-27-26 08:00AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing (GlobeNewswire)
May-19-26 04:45PM	Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
May-18-26 08:30AM	Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
May-14-26 04:50PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press)
04:10PM	Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-26 04:01PM	Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-06-26 04:01PM	Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 (GlobeNewswire) -5.88%
May-04-26 08:30AM	Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference (GlobeNewswire)
08:30AM	Loading…
Apr-21-26 08:30AM	Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi (GlobeNewswire)
Mar-31-26 05:46PM	Fortress Biotech: Q4 Earnings Snapshot (Associated Press) -11.47%
04:05PM	Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-30-26 04:05PM	Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
Mar-25-26 04:01PM	Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-26 08:30AM	Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 (GlobeNewswire)
Feb-24-26 08:53AM	Fortress Biotechs Cyprium enters agreement to sell PRV for $205M (TipRanks)
Feb-23-26 09:24AM	UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
08:30AM	Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
Feb-05-26 12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
Jan-14-26 06:06AM	Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease (Pharmaceutical Business Review) -15.90%
Jan-13-26 07:45AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States (GlobeNewswire) -7.14%
Dec-15-25 08:00AM	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission (GlobeNewswire) +13.31%
08:30AM	Loading…
Dec-10-25 08:30AM	Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology (GlobeNewswire)
Nov-14-25 09:40AM	Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates (Zacks) +5.22%
08:40AM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-25 05:25PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-25 08:15AM	Kamada (KMDA) Misses Q3 Earnings Estimates (Zacks)
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-05-25 08:30AM	Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire)
Nov-04-25 05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-30-25 08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-24-25 08:30AM	Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 08:30AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout (GlobeNewswire)
Oct-08-25 08:30AM	Journey Medical Corporation to Participate in October 2025 Investor Conferences (GlobeNewswire)
Oct-01-25 08:05AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing (GlobeNewswire) -30.72%
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 (GlobeNewswire)
Sep-03-25 08:30AM	Journey Medical Corporation to Participate in September 2025 Investor Conferences (GlobeNewswire)
Sep-02-25 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +15.50%
Aug-18-25 08:30AM	Journey Medical Corporation to Present at the Emerging Growth Conference (GlobeNewswire) +6.13%
Aug-14-25 05:55PM	Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.16%
04:49PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-25 04:01PM	Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-25 08:10AM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 (GlobeNewswire)
Aug-05-25 04:01PM	Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-14-25 08:50AM	Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors (Zacks)
08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
Jul-10-25 09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
Jun-19-25 08:50AM	Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock (Zacks)
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire) +6.50%
Jun-03-25 08:50AM	Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-30-25 10:47AM	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics (GlobeNewswire)
May-16-25 05:50AM	New Strong Sell Stocks for May 16th (Zacks)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.23%
04:25PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-14-25 05:15PM	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.45%
04:15PM	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates (GlobeNewswire)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.94%
Mar-26-25 07:39PM	Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire)
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire)
Mar-17-25 08:55AM	Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-09-25 10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire)
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire)
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-28-25 08:41AM	Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex (TipRanks)
07:21AM	Fortress doses first subject in Phase II CMV vaccine trial (Clinical Trials Arena)

Show Previous News

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Executive ChairmanDr. Lindsay Allan Rosenwald M.D.

CFO & Head of Corporate DevelopmentMr. David Jin

Chief Strategy OfficerDr. Xiaoqin Lu M.D.

J.D.Mr. Michael S. Weiss Esq.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBIO

Fortress Biotech Inc

Upgrade your Finviz experience